Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
DENVER, March 08, 2017 -- Global CBD cannabis innovator Elixinol has announced the launch of Respira, a versatile, full-spectrum cannabidiol (CBD) tincture line.
|
||||||||||||||||||||
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/802dcf21-081a-4a7a-8b3f-0296cd7f69e6
http://www.globenewswire.com/NewsRoom/AttachmentNg/3c75f9df-ec94-4722-a0f9-5645e457d5bd
http://www.globenewswire.com/NewsRoom/AttachmentNg/65cb132e-206e-47e4-8f54-42bbcd1c3b4d
http://www.globenewswire.com/NewsRoom/AttachmentNg/cfa76333-fc69-49d1-9e69-75a688e06670
Elixinol has developed Respira with all natural ingredients, making Respira a multi-purpose CBD product suitable for consumption orally, topically, or by vape.
As CBD gains in popularity as a cannabis product without psychoactive properties, consumers are seeking ways to incorporate CBD into their daily lives including topical, digestive and vape oil.
“Respira is our most versatile tincture to date, the customer has complete control over the delivery mechanisms,” said Chris Husong, Director of Marketing and Sales of Elixinol. “As cannabis and CBD customers become more educated, we will continue to develop convenient, high-quality products designed for how our customers are using CBD today.”
Each 10 mg serving size of Respira delivers high concentrations of either 300 mg or 600 mg of CBD oil. Respira is sold in two refreshing flavors, grape-mint and natural.
“I use Respira to ease anxiety, pain and headaches associated with my chronic traumatic encephalopathy (CTE). I can use this as a vape oil in my vape pen when I’m on the go,” said CBD advocate and New York Giants Super Bowl champion Leonard Marshall. “This is a product formulated for busy people like me, and it allows me to be my best me.”
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products globally in the United States, Japan, Puerto Rico and the UK. More information is available at Elixinol.com.
Media Contact: Chris Husong Elixinol 844-804-3504 ext 420 [email protected]
